Waters Corporation — Wall Street Analyst Estimates & Price Targets

WAT

NYSEHealthcareMedical - Diagnostics & ResearchCIK 0001000697waters.comAbout WAT

Last close · Oct 16, 2026436.95−7.20 (−1.62%)

Market cap$42.9B

10 firms' latest targets, last 90 days: median $477.50 ($400.00–$515.00), 9% above the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker

Each firm's latest target

last 90 days · 10 firms

Date	Firm	Target	Previous	Change	Vs price then	Vs price now
2026-10-07	Barclays	$500.00	$460.00	▲ 9%	+15%	+14%
2026-10-01	Guggenheim	$490.00	$440.00	▲ 11%	+12%	+12%
2026-09-21	Goldman Sachs	$515.00	$425.00	▲ 21%	+22%	+18%
2026-09-09	UBS	$490.00	$375.00	▲ 31%	+22%	+12%
2026-08-27	Piper Sandler	$480.00	$400.00	▲ 20%	+16%	+10%
2026-08-05	Morgan Stanley	$430.00	$390.00	▲ 10%	+7%	-2%
2026-08-05	Deutsche Bank	$400.00	$350.00	▲ 14%	+0%	-8%
2026-08-05	Evercore ISI	$420.00	$410.00	▲ 2%	+7%	-4%
2026-08-05	RBC Capital	$475.00	$435.00	▲ 9%	+20%	+9%
2026-08-05	Stifel	$420.00	—	—	+6%	-4%

Consensus estimates

revenue and EPS by fiscal year · reported years marked

FY	Revenue	YoY	EPS	YoY	Revenue range	EPS range	Analysts
2023reported	$3.0B	-1%	$10.84	-8%	est. $3.0B+0%	est. $11.69	12
2024reported	$3.0B	+0%	$10.71	-1%	est. $2.9B+1%	est. $11.80	12
2025reported	$3.2B	+7%	$10.76	+0%	est. $3.2B+0%	est. $13.11	14
2026	$6.5B	+104%	$14.58	+11%	$6.4B–$6.5B	$14.52–$14.63	17
2027	$7.1B	+10%	$16.49	+13%	$7.0B–$7.3B	$15.95–$17.73	17
2028	$7.5B	+6%	$18.41	+12%	$7.4B–$8.0B	$14.70–$22.39	17
2029	$8.0B	+7%	$20.36	+11%	$8.0B–$8.3B	$20.07–$21.14	13
2030	$8.5B	+6%	$22.15	+9%	$8.4B–$8.7B	$21.84–$23.00	8

A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

The analysts at a glance

$477.50median target, 9% above the last close

Firms with a target · last 90 days: 10
Lowest – highest target: $400.00 – $515.00
Current grades of 16 firms: positive / neutral / negative: 11 / 5 / 0
Upgrades / downgrades · 12 months: 4 / 0
Consensus revenue growth · next 3 FY: +34% a year

Current grades

each firm's latest · 16 firms

As of	Firm	Grade
2026-10-13	TD Cowen	“Buy”
2026-10-07	Barclays	“Overweight”
2026-10-01	Guggenheim	“Buy”
2026-09-21	Goldman Sachs	“Buy”
2026-09-09	UBS	“Buy”
2026-08-27	Piper Sandler	“Overweight”
2026-08-10	Citigroup	“Buy”
2026-08-05	Evercore ISI	“Outperform”
2026-08-05	RBC Capital	“Outperform”
2026-08-05	Wells Fargo	“Equal Weight”

6 more

2026-07-09	Morgan Stanley	“Equal Weight”
2026-06-03	HSBC	“Buy”
2026-06-02	Bank of America	“Neutral”
2026-05-06	J.P. Morgan	“Neutral”
2026-03-25	Deutsche Bank	“Hold”
2025-12-10	Wolfe Research	“Outperform”

Grade changes

last 24 months · 9

Date	Firm	Grade
2026-09-09	UBS	“Neutral” → “Buy” upgrade
2026-08-27	Piper Sandler	“Neutral” → “Overweight” upgrade
2026-08-05	TD Cowen	“Hold” → “Buy” upgrade
2025-12-10	Wolfe Research	“Peer Perform” → “Outperform” upgrade
2025-07-15	Wells Fargo	“Overweight” → “Equal Weight” downgrade
2025-03-31	Keybanc	“Sector Weight” → “Overweight” upgrade
2025-03-26	Baird	“Neutral” → “Outperform” upgrade
2025-02-13	Scotiabank	“Sector Perform” → “Sector Outperform” upgrade
2025-02-10	Barclays	“Underweight” → “Equal Weight” upgrade

37 older than 24 months

2024-10-08	Jefferies	“Hold” → “Buy” upgrade
2024-08-01	Leerink Partners	“Market Perform” → “Outperform” upgrade
2023-11-13	Barclays	“Equal Weight” → “Underweight” downgrade
2023-07-31	Barclays	“Overweight” → “Equal Weight” downgrade
2023-07-31	Evercore ISI	“Outperform” → “In Line” downgrade
2023-07-20	Leerink Partners	“Market Perform” → “Perform” revised
2022-05-17	Bank of America	“Underperform” → “Neutral” upgrade
2022-04-25	Wells Fargo	“Underweight” → “Equal Weight” upgrade
2021-07-06	Evercore ISI	“In Line” → “Outperform” upgrade
2021-01-07	Wells Fargo	“Equal Weight” → “Underweight” downgrade
2020-12-16	Citigroup	“Sell” → “Neutral” upgrade
2020-07-16	Wells Fargo	“Underweight” → “Equal Weight” upgrade
2020-01-08	Needham	“Hold” → “Underperform” downgrade
2019-12-05	BTIG Research	“Buy” → “Neutral” downgrade
2019-10-09	Barclays	“Equal Weight” → “Underweight” downgrade
2019-07-16	Bank of America	“Neutral” → “Underperform” downgrade
2019-01-24	Baird	“Outperform” → “Neutral” downgrade
2019-01-03	Bank of America	“Underperform” → “Neutral” upgrade
2018-12-12	J.P. Morgan	“Neutral” → “Underweight” downgrade
2018-11-30	Goldman Sachs	“Neutral” → “Sell” downgrade
2018-10-08	Leerink Partners	“Outperform” → “Market Perform” downgrade
2018-07-17	Janney Montgomery Scott	“Buy” → “Neutral” downgrade
2018-07-16	Bank of America	“Neutral” → “Underperform” downgrade
2017-12-04	Morgan Stanley	“Underweight” → “Equal Weight” upgrade
2017-07-10	Deutsche Bank	“Buy” → “Hold” downgrade
2017-05-01	Janney Montgomery Scott	“Neutral” → “Buy” upgrade
2017-01-06	William Blair	“Market Perform” → “Outperform” upgrade
2016-04-05	Bank of America	“Buy” → “Neutral” downgrade
2015-07-29	Wells Fargo	“Market Perform” → “Outperform” upgrade
2013-10-23	Bank of America	“Buy” → “Neutral” downgrade
2013-10-14	Mizuho	“Buy” → “Neutral” downgrade
2013-06-25	Goldman Sachs	“Neutral” → “Buy” upgrade
2013-01-23	Gabelli & Co.	“Buy” → “Hold” downgrade
2013-01-17	Wells Fargo	“Outperform” → “Market Perform” downgrade
2013-01-04	Morgan Stanley	“Overweight” → “Equal Weight” downgrade
2013-01-03	J.P. Morgan	“Overweight” → “Neutral” downgrade
2013-01-03	Leerink Partners	“Outperform” → “Market Perform” downgrade

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.